Evicenter
Xarelto (rivaroxaban) in Nonvalvular atrial fibrillation
Manufacturer
Janssen Pharmaceuticals, Inc.
Prescribing information
Xarelto (opens in a new tab)
Questions
17
Last updated

All questions

Real-world evidence: Xarelto (rivaroxaban) in nonvalvular atrial fibrillation

1 question · 1 source

Real-world evidence

Xarelto vs Eliquis: what did a real-world study in Israel show?

Note: This is a retrospective observational comparison of two cohorts in Israel. The first multiplicity footnote belongs to the effectiveness result and the second to the bleeding table. The page text gives no hazard ratio or confidence interval for ischemic stroke. In the bleeding table each row gives the outcome, the number of patients in each cohort, the event-rate statement, and the hazard ratio (95% CI) for XARELTO vs Eliquis. The page does not state the doses either cohort received. The Eliquis questions in this collection quote observational analyses from the Eliquis HCP site with results in the other direction, and the Eliquis statement that there are currently no results from clinical trials comparing the two products for stroke risk reduction in NVAF.